7DVY image
Entry Detail
PDB ID:
7DVY
Keywords:
Title:
SARS-CoV-2 Mpro mutant (H41A) in complex with nsp9|10 peptidyl substrate
Biological Source:
PDB Version:
Deposition Date:
2021-01-15
Release Date:
2022-01-19
Method Details:
Experimental Method:
Resolution:
1.80 Å
R-Value Free:
0.21
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:3C-like proteinase
Mutations:H41A
Chain IDs:A
Chain Length:306
Number of Molecules:1
Biological Source:Severe acute respiratory syndrome coronavirus 2
Polymer Type:polypeptide(L)
Description:nsp9/10 peptidyl substrate
Chain IDs:B (auth: C)
Chain Length:20
Number of Molecules:1
Biological Source:Severe acute respiratory syndrome coronavirus 2
Primary Citation
Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2.
Proc.Natl.Acad.Sci.USA 119 e2117142119 e2117142119 (2022)
PMID: 35380892 DOI: 10.1073/pnas.2117142119

Abstact

The main protease (Mpro) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a key enzyme, which extensively digests CoV replicase polyproteins essential for viral replication and transcription, making it an attractive target for antiviral drug development. However, the molecular mechanism of how Mpro of SARS-CoV-2 digests replicase polyproteins, releasing the nonstructural proteins (nsps), and its substrate specificity remain largely unknown. Here, we determine the high-resolution structures of SARS-CoV-2 Mpro in its resting state, precleavage state, and postcleavage state, constituting a full cycle of substrate cleavage. The structures show the delicate conformational changes that occur during polyprotein processing. Further, we solve the structures of the SARS-CoV-2 Mpro mutant (H41A) in complex with six native cleavage substrates from replicase polyproteins, and demonstrate that SARS-CoV-2 Mpro can recognize sequences as long as 10 residues but only have special selectivity for four subsites. These structural data provide a basis to develop potent new inhibitors against SARS-CoV-2.

Legend

Protein

Chemical

Disease

Primary Citation of related structures